wickw50
2 weeks ago
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Revenues Services $267,371 $587,893 $764,062 $1,740,880 License fees 1,441,011 950,015 4,165,669 3,764,342 Hardware 436,422 279,200 537,562 424,582 Total revenues 2,144,804 1,817,108 5,467,293 5,929,804 Costs and other expenses Cost of services 110,723 125,039 322,957 639,996 Cost of license fees 146,732 253,891 443,384 1,022,919 Cost of hardware 207,655 97,674 260,684 240,074 Cost of hardware - reserve - 1,000,000 - 2,500,000 Total costs and other expenses 465,110 1,476,604 1,027,025 4,402,989 Gross profit 1,679,694 340,504 4,440,268 1,526,815 Operating Expenses Selling, general and administrative 1,607,925 1,776,305 5,332,764 5,851,201 Research, development and engineering 652,174 529,757 1,850,929 1,778,097 Total Operating Expenses 2,260,099 2,306,062 7,183,693 7,629,298 Operating loss (580,405) (1,965,558) (2,743,425) (6,102,483)Other income (expense) Interest income 2 5,917 53 5,944 Loss on foreign currency transactions - - - (15,000)Loan fee amortization (60,000) - (64,000) - Change in fair value of convertible note - 167,283 - 264,706 Interest expense (98,556) (45,655) (108,823) (159,380)Total other income (expense), net (158,554) 127,545 (172,770) 96,270 Loss before provision for income tax (738,959) (1,838,013) (2,916,195) (6,006,213) Provision for (income tax) tax benefit - 189 - (142,811) Net loss $(738,959) $(1,837,824) $(2,916,195) $(6,149,024) Comprehensive loss: Net loss $(738,959) $(1,837,824) $(2,916,195) $(6,149,024)Other comprehensive income (loss) – Foreign currency translation adjustment 89,933 35,364 51,878 127,394 Comprehensive loss $(649,026) $(1,802,460) $(2,864,317) $(6,021,630) Basic and Diluted Loss per Common Share $(0.39) $(3.22) $(1.69) $(10.79) Weighted Average Common Shares Outstanding: Basic and diluted 1,889,694 570,753 1,726,716 569,882 All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.
wickw50
3 months ago
BIO-key Reports Reduced Net Loss and Cash Used in Operations on Lower Q2’24 Revenues; Hosts Investor Call Thu. Aug. 15th at 10am ET
HOLMDEL, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, announced results for its second quarter ended June 30, 2024 (Q2’24). Note, BIO-key’s results for 2023 were restated at year-end and filed with the Company’s 2023 Form 10-K, and as a result Q2’23 and six months ended June 30, 2023 comparisons in this release have been restated. BIO-key will host an investor call Thursday, August 15th at 10:00am ET (details below).
Financial Highlights
Q2’24 revenues decreased to $1.1M from $1.9M in Q2’23, principally due to a delay in recognition of approximately $450,000 in software license fees generated by the Company’s European subsidiary and lower project-related services revenue of approximately $200,000 as compared to the year-ago period for one large customer.
Gross profit improved to $0.9M (77.0% gross margin) in Q2’24 vs. $0.3M (16.7% gross margin) in Q2’23, primarily reflecting the impact of a $1M hardware reserve in Q2’23.
BIO-key trimmed Q2’24 operating expenses by $0.2M versus Q2’23, reflecting ongoing cost management initiatives.
BIO-key reported a Q2’24 net loss of $1.7M compared to a Q2’23 net loss of $2.6M, primarily due to a $1M hardware reserve in Q2’23.
Cash used in operating activities improved 48% to $1.1M in the first six months of 2024 vs. $2.1M used in the first six months of 2023. Improved operating cash flow reflects the benefit of a Q1’24 $1.5M 2-year extension/expansion of a biometric technology license with a long-term financial services customer and continued reductions in S,G &A.
Recent Business Highlights
Williamsburg, VA advanced its Zero Trust initiative with BIO-key’s Identity-Bound Biometrics.
Los Angeles LGBT Center secured its IT Systems with BIO-key’s Seamless Badge-Tap Authentication Solution.
University of Iowa Hospital and Dayton Children’s Hospital) expanded their BIO-key deployments in Q2’24.
BIO-key introduced Passkey:YOU, a phish-resistant, phoneless and tokenless biometric FIDO Passkey Authentication Solution.
BIO-key won the Global InfoSec Award for Multi-factor Authentication at RSA Conference 2024.
Commentary
BIO-key CEO, Mike DePasquale commented, “Q2 was impacted by delays we experienced in the closing of approximately $450,000 in software license contracts and lower non-recurring, project-related services revenue of approximately $200,000 versus the year-ago period for one large customer in 2023.
“Despite our lower than expected revenues this quarter, we remain very encouraged by the growing enterprise awareness of the importance of implementing secure, zero-trust Identity and Access Management solutions which form the core of our offerings. We remain focused on driving revenue growth and progressing our business to profitability and positive cash flow over the next several quarters. We are working to support our Channel Alliance Partners around the globe while also working to progress larger-scale customer dialogues via our in-house direct sales efforts.
“We are also excited by the growth potential for our new Passkey:YOU solution which we believe provides a very powerful, differentiated solution within the rapidly expanding deployment of passkey solutions by some of the largest global companies. Unlike other solutions, BIO-key’s Passkey:YOU utilizes our industry leading biometric technology to deliver a unique passwordless and device-less authentication solution able to meet a broad range of needs, including some of the most challenging use cases.
“We continue to expect to benefit from the rollout and enforcement of increasingly stringent regulatory standards and cyber insurance underwriting requirements, much of which are now mandating multi-factor authentication or passwordless security solutions that BIO-key is well positioned to provide on a very competitive basis.
“Given our size, our performance will likely remain variable on a quarter to quarter and year over year basis, based on the impact and timing of customer contracts, though we remain confident in our ability to drive sequential growth on a full year basis. Importantly, we are building a growing base of high-margin annually recurring revenues (ARRs) with solid potential to expand as we move forward. We also continue to seek and implement cost reduction opportunities and identify potential strategic opportunities to leverage our core expertise to accelerate our path to profitability and positive cash flow. For these and other reasons, we believe BIO-key is well-positioned for the future.”
Financial Results
BIO-key reported Q2’24 revenues of $1.1M compared to $1.9M in Q2’23. The current-year period was negatively impacted by the delay in recognition of approximately $450,000 in software license fees generated by the Company’s European subsidiary and the year-ago period benefitted from approximately $200,000 of non-recurring services revenue for one large customer. For the six months ended June 30, 2024, revenues were $3.3M compared to $4.1M in 2023, principally due to the factors that impacted Q2’24 results.
Q2’24 Gross profit was $0.9M (77.0% gross margin) versus $0.3M (16.7% gross margin) in Q2’23, primarily reflecting the impact of a $1M hardware reserve in 2023 and higher gross margins from services in Q2’24.
BIO-key was able to reduce operating expenses by $0.2M in Q2’24 versus Q2’23, reflecting reductions in administration, sales personnel costs and marketing show expenses, including lower headquarters expense. Partially offsetting lower SG&A costs, was a $33,000 increase in research, development and engineering expense related to new product development.
Reflecting lower costs and the $1M hardware reserve in 2023, BIO-key’s net loss improved to $1.7M, or $1.00 per share, in Q2’24, from $2.6M, or $4.71 per share, in Q2’23. Likewise, BIO-key trimmed its net loss for the first six months of 2024 to $2.2M, or $1.33 per share, compared to a net loss of $4.3M, or $7.74 per share, in the first six months of 2023. Q2’23 results included a hardware reserve of $1M and the first six months of 2023 included a hardware reserve of $1.5M.
Balance Sheet
At June 30, 2024, BIO-key had current assets of approximately $3.0M, including $1.3M of cash and cash equivalents, $932,210 of net accounts receivable and due from factor, and $433,182 of inventory. This compares to current assets of approximately $2.6M, including $511,400 of cash equivalents, $1.3M of net accounts receivable and due from factor, and $445,740 of inventory, at December 31, 2023.
Conference Call Details
Date / Time: Thursday, August 15th at 10 a.m. ET
Call Dial In #: 1-877-418-5460 U.S. or 1-412-717-9594 Int’l
Live Webcast / Replay: Webcast & Replay Link – Available for 3 months.
Audio Replay: 1-877-344-7529 U.S. or 1-412-317-0088 Int’l; code 7767803
About BIO-key International, Inc. (www.BIO-key.com)
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.
BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; our ability to integrate the operations and personnel of Swivel Secure into our business; fluctuations in foreign currency exchange rates; delays in the development of products, the commercial, reputational and regulatory risks to our business that may arise as a consequence the restatement of our financial statements, including any consequences of non-compliance with Securities and Exchange Commission and Nasdaq periodic reporting requirements; our temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future; if we fail to increase our stockholders’ equity to at least $2.5 million, our common stock will be delisted from the Nasdaq Capital Market which could negatively impact the trading price of our common stock and impair our ability to raise capital, any disruption to our business that may occur on a longer-term basis should we be unable to remediate during fiscal year 2024 certain material weaknesses in our internal controls over financial reporting, and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
Engage with BIO-key
Facebook – Corporate: https://www.facebook.com/BIOkeyInternational/
LinkedIn – Corporate: https://www.linkedin.com/company/bio-key-international
X – Corporate: @BIOkeyIntl
X – Investors: @BIO_keyIR
StockTwits: BIO_keyIR
Investor Contacts
William Jones, David Collins
Catalyst IR
BKYI @Bacchus-9800
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
2024 2023 2024 2023
Revenues
Services $ 283,569 $ 620,465 $ 496,690 $ 1,152,987
License fees 774,225 1,235,771 2,724,659 2,814,327
Hardware 83,492 72,693 101,140 145,382
Total revenues 1,141,286 1,928,929 3,322,489 4,112,696
Costs and other expenses
Cost of services 73,385 360,156 212,234 514,957
Cost of license fees 148,432 198,147 296,652 819,028
Cost of hardware 40,455 47,808 53,029 92,400
Cost of hardware - reserve - 1,000,000 - 1,500,000
Total costs and other expenses 262,272 1,606,111 561,915 2,926,385
Gross profit 879,014 322,818 2,760,574 1,186,311
Operating Expenses
Selling, general and administrative 1,941,866 2,143,164 3,724,839 4,074,896
Research, development and engineering 591,234 558,181 1,198,755 1,248,340
Total Operating Expenses 2,533,100 2,701,345 4,923,594 5,323,236
Operating loss (1,654,086 ) (2,378,527 ) (2,163,020 ) (4,136,925 )
Other income (expense)
Interest income 46 23 51 27
Loss on foreign currency transactions - - - (15,000 )
Loan fee amortization (4,000 ) - (4,000 ) -
Change in fair value of convertible note - (44,568 ) - 97,423
Interest expense (8,910 ) (56,806 ) (10,267 ) (113,725 )
Total other income (expense), net (12,864 ) (101,351 ) (14,216 ) (31,275 )
Loss before provision for income tax (1,666,950 ) (2,479,878 ) (2,177,236 ) (4,168,200 )
Provision for (income tax) tax benefit - (143,000 ) - (143,000 )
Net loss $ (1,666,950 ) $ (2,622,878 ) $ (2,177,236 ) $ (4,311,200 )
Comprehensive loss:
Net loss $ (1,666,950 ) $ (2,622,878 ) $ (2,177,236 ) $ (4,311,200 )
Other comprehensive income (loss) – Foreign currency translation adjustment 24,220 19,884 (38,530 ) 92,030
Comprehensive loss $ (1,642,730 ) $ (2,602,994 ) $ (2,215,766 ) $ (4,219,170 )
Basic and Diluted Loss per Common Share $ (1.00 ) $ (4.71 ) $ (1.33 ) $ (7.74 )
Weighted Average Common Shares Outstanding:
Basic and diluted 1,663,042 556,758 1,639,183 556,758
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, December 31,
2024 2023
(Unaudited)
ASSETS
Cash and cash equivalents $ 1,260,351 $ 511,400
Accounts receivable, net 904,046 1,201,526
Due from factor 28,164 99,320
Inventory 433,182 445,740
Prepaid expenses and other 388,786 364,171
Total current assets 3,014,529 2,622,157
Equipment and leasehold improvements, net 174,419 220,177
Capitalized contract costs, net 348,617 229,806
Operating lease right-of-use assets 9,341 36,905
Intangible assets, net 1,252,090 1,407,990
Total non-current assets 1,784,467 1,894,878
TOTAL ASSETS $ 4,798,996 $ 4,517,035
LIABILITIES
Accounts payable $ 1,539,548 $ 1,316,014
Accrued liabilities 1,164,681 1,305,848
Note payable 2,010,293 -
Government loan – BBVA Bank, current portion 135,400 138,730
Deferred revenue, current 715,193 414,968
Operating lease liabilities, current portion 9,570 37,829
Total current liabilities 5,574,685 3,213,389
Deferred revenue, long term 142,949 28,296
Deferred tax liability 22,998 22,998
Government loan – BBVA Bank – net of current portion 114,656 188,787
Total non-current liabilities 280,603 240,081
TOTAL LIABILITIES 5,855,288 3,453,470
Commitments and Contingencies
STOCKHOLDERS’ EQUITY
Common stock — authorized, 170,000,000 shares; issued and outstanding; 1,815,618 and 1,032,777 of $.0001 par value at June 30, 2024 and December 31, 2023, respectively 182 103
Additional paid-in capital 126,143,205 126,047,851
Accumulated other comprehensive loss (15,234 ) 22,821
Accumulated deficit (127,184,445 ) (125,007,210 )
TOTAL STOCKHOLDERS’ EQUITY (1,056,292 ) 1,063,565
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 4,798,996 $ 4,517,035
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Six Months Ended June 30,
2024 2023
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss $ (2,177,236 ) $ (4,311,200 )
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation 46,069 26,637
Amortization of intangible assets 155,900 162,166
Change in fair value of convertible note - (97,423 )
Amortization of capitalized contract costs 80,074 80,717
Reserve for inventory - 1,500,000
Operating leases right-of-use assets 27,564 112,745
Share and warrant-based compensation for employees and consultants 96,561 120,767
Stock based directors’ fees 9,003 28,004
Deferred income tax benefit (13,000 )
Bad debts 250,000
Change in assets and liabilities:
Accounts receivable 297,480 (757,170 )
Due from factor 71,156 (24,750 )
Capitalized contract costs (198,885 ) (75,096 )
Inventory 12,558 50,271
Prepaid expenses and other (24,615 ) 14,799
Accounts payable 258,384 726,657
Accrued liabilities (141,167 ) (109,208 )
Income taxes payable - 156,000
Deferred revenue 414,878 174,437
Operating lease liabilities (51,257 ) (110,545 )
Net cash used in operating activities (1,123,533 ) (2,095,192 )
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures (1,869 ) -
Net cash used in investing activities (1,869 ) -
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from Note Payable 2,000,000 -
Offering costs (13,470 ) -
Proceeds for exercise of warrants 1,400 -
Receipt of cash from Employee stock purchase plan 1,939 13,934
Repayment of government loan (77,461 ) (56,241 )
Net cash used in financing activities 1,912,408 (42,307 )
Effect of exchange rate changes (38,055 ) 67,490
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 748,951 (2,070,009 )
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 511,400 2,635,522
CASH AND CASH EQUIVALENTS, END OF PERIOD $ 1,260,351 $ 565,513
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.
This message was distributed by GlobeNewswire.
2321 Rosecrans Ave. Ste 2200, El Segundo, CA, 90245, USA. +1-800-307-6627. www.globenewswire.com
On behalf of BIO-key International, Inc. 3349 Highway 138 Building A Suite E, Wall Township, NJ 07719 US bio-key.com
wickw50
3 months ago
BIO-key Reports Reduced Net Loss and Cash Used in Operations on Lower Q2’24 Revenues; Hosts Investor Call Thu. Aug. 15th at 10am ET
HOLMDEL, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, announced results for its second quarter ended June 30, 2024 (Q2’24). Note, BIO-key’s results for 2023 were restated at year-end and filed with the Company’s 2023 Form 10-K, and as a result Q2’23 and six months ended June 30, 2023 comparisons in this release have been restated. BIO-key will host an investor call Thursday, August 15th at 10:00am ET (details below).
Financial Highlights
Q2’24 revenues decreased to $1.1M from $1.9M in Q2’23, principally due to a delay in recognition of approximately $450,000 in software license fees generated by the Company’s European subsidiary and lower project-related services revenue of approximately $200,000 as compared to the year-ago period for one large customer.
Gross profit improved to $0.9M (77.0% gross margin) in Q2’24 vs. $0.3M (16.7% gross margin) in Q2’23, primarily reflecting the impact of a $1M hardware reserve in Q2’23.
BIO-key trimmed Q2’24 operating expenses by $0.2M versus Q2’23, reflecting ongoing cost management initiatives.
BIO-key reported a Q2’24 net loss of $1.7M compared to a Q2’23 net loss of $2.6M, primarily due to a $1M hardware reserve in Q2’23.
Cash used in operating activities improved 48% to $1.1M in the first six months of 2024 vs. $2.1M used in the first six months of 2023. Improved operating cash flow reflects the benefit of a Q1’24 $1.5M 2-year extension/expansion of a biometric technology license with a long-term financial services customer and continued reductions in S,G &A.
Recent Business Highlights
Williamsburg, VA advanced its Zero Trust initiative with BIO-key’s Identity-Bound Biometrics.
Los Angeles LGBT Center secured its IT Systems with BIO-key’s Seamless Badge-Tap Authentication Solution.
University of Iowa Hospital and Dayton Children’s Hospital) expanded their BIO-key deployments in Q2’24.
BIO-key introduced Passkey:YOU, a phish-resistant, phoneless and tokenless biometric FIDO Passkey Authentication Solution.
BIO-key won the Global InfoSec Award for Multi-factor Authentication at RSA Conference 2024.
Commentary
BIO-key CEO, Mike DePasquale commented, “Q2 was impacted by delays we experienced in the closing of approximately $450,000 in software license contracts and lower non-recurring, project-related services revenue of approximately $200,000 versus the year-ago period for one large customer in 2023.
“Despite our lower than expected revenues this quarter, we remain very encouraged by the growing enterprise awareness of the importance of implementing secure, zero-trust Identity and Access Management solutions which form the core of our offerings. We remain focused on driving revenue growth and progressing our business to profitability and positive cash flow over the next several quarters. We are working to support our Channel Alliance Partners around the globe while also working to progress larger-scale customer dialogues via our in-house direct sales efforts.
“We are also excited by the growth potential for our new Passkey:YOU solution which we believe provides a very powerful, differentiated solution within the rapidly expanding deployment of passkey solutions by some of the largest global companies. Unlike other solutions, BIO-key’s Passkey:YOU utilizes our industry leading biometric technology to deliver a unique passwordless and device-less authentication solution able to meet a broad range of needs, including some of the most challenging use cases.
“We continue to expect to benefit from the rollout and enforcement of increasingly stringent regulatory standards and cyber insurance underwriting requirements, much of which are now mandating multi-factor authentication or passwordless security solutions that BIO-key is well positioned to provide on a very competitive basis.
“Given our size, our performance will likely remain variable on a quarter to quarter and year over year basis, based on the impact and timing of customer contracts, though we remain confident in our ability to drive sequential growth on a full year basis. Importantly, we are building a growing base of high-margin annually recurring revenues (ARRs) with solid potential to expand as we move forward. We also continue to seek and implement cost reduction opportunities and identify potential strategic opportunities to leverage our core expertise to accelerate our path to profitability and positive cash flow. For these and other reasons, we believe BIO-key is well-positioned for the future.”
Financial Results
BIO-key reported Q2’24 revenues of $1.1M compared to $1.9M in Q2’23. The current-year period was negatively impacted by the delay in recognition of approximately $450,000 in software license fees generated by the Company’s European subsidiary and the year-ago period benefitted from approximately $200,000 of non-recurring services revenue for one large customer. For the six months ended June 30, 2024, revenues were $3.3M compared to $4.1M in 2023, principally due to the factors that impacted Q2’24 results.
Q2’24 Gross profit was $0.9M (77.0% gross margin) versus $0.3M (16.7% gross margin) in Q2’23, primarily reflecting the impact of a $1M hardware reserve in 2023 and higher gross margins from services in Q2’24.
BIO-key was able to reduce operating expenses by $0.2M in Q2’24 versus Q2’23, reflecting reductions in administration, sales personnel costs and marketing show expenses, including lower headquarters expense. Partially offsetting lower SG&A costs, was a $33,000 increase in research, development and engineering expense related to new product development.
Reflecting lower costs and the $1M hardware reserve in 2023, BIO-key’s net loss improved to $1.7M, or $1.00 per share, in Q2’24, from $2.6M, or $4.71 per share, in Q2’23. Likewise, BIO-key trimmed its net loss for the first six months of 2024 to $2.2M, or $1.33 per share, compared to a net loss of $4.3M, or $7.74 per share, in the first six months of 2023. Q2’23 results included a hardware reserve of $1M and the first six months of 2023 included a hardware reserve of $1.5M.
Balance Sheet
At June 30, 2024, BIO-key had current assets of approximately $3.0M, including $1.3M of cash and cash equivalents, $932,210 of net accounts receivable and due from factor, and $433,182 of inventory. This compares to current assets of approximately $2.6M, including $511,400 of cash equivalents, $1.3M of net accounts receivable and due from factor, and $445,740 of inventory, at December 31, 2023.
Conference Call Details
Date / Time: Thursday, August 15th at 10 a.m. ET
Call Dial In #: 1-877-418-5460 U.S. or 1-412-717-9594 Int’l
Live Webcast / Replay: Webcast & Replay Link – Available for 3 months.
Audio Replay: 1-877-344-7529 U.S. or 1-412-317-0088 Int’l; code 7767803
About BIO-key International, Inc. (www.BIO-key.com)
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.
BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; our ability to integrate the operations and personnel of Swivel Secure into our business; fluctuations in foreign currency exchange rates; delays in the development of products, the commercial, reputational and regulatory risks to our business that may arise as a consequence the restatement of our financial statements, including any consequences of non-compliance with Securities and Exchange Commission and Nasdaq periodic reporting requirements; our temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future; if we fail to increase our stockholders’ equity to at least $2.5 million, our common stock will be delisted from the Nasdaq Capital Market which could negatively impact the trading price of our common stock and impair our ability to raise capital, any disruption to our business that may occur on a longer-term basis should we be unable to remediate during fiscal year 2024 certain material weaknesses in our internal controls over financial reporting, and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
Engage with BIO-key
Facebook – Corporate: https://www.facebook.com/BIOkeyInternational/
LinkedIn – Corporate: https://www.linkedin.com/company/bio-key-international
X – Corporate: @BIOkeyIntl
X – Investors: @BIO_keyIR
StockTwits: BIO_keyIR
Investor Contacts
William Jones, David Collins
Catalyst IR
BKYI @Bacchus-9800
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
2024 2023 2024 2023
Revenues
Services $ 283,569 $ 620,465 $ 496,690 $ 1,152,987
License fees 774,225 1,235,771 2,724,659 2,814,327
Hardware 83,492 72,693 101,140 145,382
Total revenues 1,141,286 1,928,929 3,322,489 4,112,696
Costs and other expenses
Cost of services 73,385 360,156 212,234 514,957
Cost of license fees 148,432 198,147 296,652 819,028
Cost of hardware 40,455 47,808 53,029 92,400
Cost of hardware - reserve - 1,000,000 - 1,500,000
Total costs and other expenses 262,272 1,606,111 561,915 2,926,385
Gross profit 879,014 322,818 2,760,574 1,186,311
Operating Expenses
Selling, general and administrative 1,941,866 2,143,164 3,724,839 4,074,896
Research, development and engineering 591,234 558,181 1,198,755 1,248,340
Total Operating Expenses 2,533,100 2,701,345 4,923,594 5,323,236
Operating loss (1,654,086 ) (2,378,527 ) (2,163,020 ) (4,136,925 )
Other income (expense)
Interest income 46 23 51 27
Loss on foreign currency transactions - - - (15,000 )
Loan fee amortization (4,000 ) - (4,000 ) -
Change in fair value of convertible note - (44,568 ) - 97,423
Interest expense (8,910 ) (56,806 ) (10,267 ) (113,725 )
Total other income (expense), net (12,864 ) (101,351 ) (14,216 ) (31,275 )
Loss before provision for income tax (1,666,950 ) (2,479,878 ) (2,177,236 ) (4,168,200 )
Provision for (income tax) tax benefit - (143,000 ) - (143,000 )
Net loss $ (1,666,950 ) $ (2,622,878 ) $ (2,177,236 ) $ (4,311,200 )
Comprehensive loss:
Net loss $ (1,666,950 ) $ (2,622,878 ) $ (2,177,236 ) $ (4,311,200 )
Other comprehensive income (loss) – Foreign currency translation adjustment 24,220 19,884 (38,530 ) 92,030
Comprehensive loss $ (1,642,730 ) $ (2,602,994 ) $ (2,215,766 ) $ (4,219,170 )
Basic and Diluted Loss per Common Share $ (1.00 ) $ (4.71 ) $ (1.33 ) $ (7.74 )
Weighted Average Common Shares Outstanding:
Basic and diluted 1,663,042 556,758 1,639,183 556,758
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, December 31,
2024 2023
(Unaudited)
ASSETS
Cash and cash equivalents $ 1,260,351 $ 511,400
Accounts receivable, net 904,046 1,201,526
Due from factor 28,164 99,320
Inventory 433,182 445,740
Prepaid expenses and other 388,786 364,171
Total current assets 3,014,529 2,622,157
Equipment and leasehold improvements, net 174,419 220,177
Capitalized contract costs, net 348,617 229,806
Operating lease right-of-use assets 9,341 36,905
Intangible assets, net 1,252,090 1,407,990
Total non-current assets 1,784,467 1,894,878
TOTAL ASSETS $ 4,798,996 $ 4,517,035
LIABILITIES
Accounts payable $ 1,539,548 $ 1,316,014
Accrued liabilities 1,164,681 1,305,848
Note payable 2,010,293 -
Government loan – BBVA Bank, current portion 135,400 138,730
Deferred revenue, current 715,193 414,968
Operating lease liabilities, current portion 9,570 37,829
Total current liabilities 5,574,685 3,213,389
Deferred revenue, long term 142,949 28,296
Deferred tax liability 22,998 22,998
Government loan – BBVA Bank – net of current portion 114,656 188,787
Total non-current liabilities 280,603 240,081
TOTAL LIABILITIES 5,855,288 3,453,470
Commitments and Contingencies
STOCKHOLDERS’ EQUITY
Common stock — authorized, 170,000,000 shares; issued and outstanding; 1,815,618 and 1,032,777 of $.0001 par value at June 30, 2024 and December 31, 2023, respectively 182 103
Additional paid-in capital 126,143,205 126,047,851
Accumulated other comprehensive loss (15,234 ) 22,821
Accumulated deficit (127,184,445 ) (125,007,210 )
TOTAL STOCKHOLDERS’ EQUITY (1,056,292 ) 1,063,565
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 4,798,996 $ 4,517,035
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Six Months Ended June 30,
2024 2023
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss $ (2,177,236 ) $ (4,311,200 )
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation 46,069 26,637
Amortization of intangible assets 155,900 162,166
Change in fair value of convertible note - (97,423 )
Amortization of capitalized contract costs 80,074 80,717
Reserve for inventory - 1,500,000
Operating leases right-of-use assets 27,564 112,745
Share and warrant-based compensation for employees and consultants 96,561 120,767
Stock based directors’ fees 9,003 28,004
Deferred income tax benefit (13,000 )
Bad debts 250,000
Change in assets and liabilities:
Accounts receivable 297,480 (757,170 )
Due from factor 71,156 (24,750 )
Capitalized contract costs (198,885 ) (75,096 )
Inventory 12,558 50,271
Prepaid expenses and other (24,615 ) 14,799
Accounts payable 258,384 726,657
Accrued liabilities (141,167 ) (109,208 )
Income taxes payable - 156,000
Deferred revenue 414,878 174,437
Operating lease liabilities (51,257 ) (110,545 )
Net cash used in operating activities (1,123,533 ) (2,095,192 )
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures (1,869 ) -
Net cash used in investing activities (1,869 ) -
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from Note Payable 2,000,000 -
Offering costs (13,470 ) -
Proceeds for exercise of warrants 1,400 -
Receipt of cash from Employee stock purchase plan 1,939 13,934
Repayment of government loan (77,461 ) (56,241 )
Net cash used in financing activities 1,912,408 (42,307 )
Effect of exchange rate changes (38,055 ) 67,490
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 748,951 (2,070,009 )
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 511,400 2,635,522
CASH AND CASH EQUIVALENTS, END OF PERIOD $ 1,260,351 $ 565,513
wickw50
5 months ago
HOLMDEL, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, announced results for its first quarter ended March 31, 2024 (Q1’24). Note, BIO-key’s results for the first three quarters of 2023 were restated at year-end and filed with the Company’s 2023 Form 10-K, and as a result Q1’23 comparisons in this release have been restated. BIO-key will host an investor call Tuesday, June 18th at 10:00am ET (details below).
Q1 Financial Highlights
Q1’24 revenues of $2.2M were in line with Q1’23 and increased 19.5% from Q4’23 revenues of $1.8M
Gross profit increased to $1.9M (86.3% gross margin) from $0.9M (40% gross margin) in Q1’23, reflecting the impact of a Q1’23 $0.5M hardware inventory reserve, as well as higher software license fees in Q1’23 due to higher royalty payments on third-party software solutions.
Operating expenses were reduced over $0.2M in Q1’24 versus Q1’23, reflecting ongoing cost management initiatives.
BIO-key reported a Q1’24 net loss of $0.5M compared to a net loss of $1.7M in Q1’23
Cash generated from operating activities improved to $0.3M in Q1’24 vs. a $1.9M cash used in Q1’23, principally reflecting the benefit of a $1.5M cash payment in Q1’24 for 2-year extension/expansion of biometric technology license with a long-term financial services customer.
Other Recent Software Deployments:
Fargo, ND and Junction City, KS Chose PortalGuard with Biometric Authentication
Bridgetown, Barbados Credit Union Selected PortalGuard with Biometrics for Shared Workstations
Commentary
BIO-key CEO, Mike DePasquale commented, “BIO-key delivered solid progress in Q1’24, achieving positive cash flow from operations in the period, on revenue of $2.2M, representing a 19.5% increase over Q4’23 and roughly flat with the year-ago period. The current-year period benefitted from the expanded deployment of BIO-key’s biometric client identification system used by a long-standing financial services client. We also further trimmed operating expenses during Q1’24, contributing to our improved bottom-line performance.
“We remain focused on driving revenue growth and progressing our business to profitability and positive cash flow over the next several quarters. We are encouraged by the traction building within our global Channel Alliance Partner program and with the larger-scale customer dialogues in which we are engaged through our in-house direct sales effort. We believe the cybersecurity landscape continues to provide a compelling backdrop for our company, as we expect it will generate increased demand for secure, zero-trust Identity and Access Management solutions that are the core of our offerings.
“Tailwinds that we expect to support our growth include a growing proportion of enterprises that are moving IT infrastructure to the cloud as well as increasingly stringent regulatory standards as well as cyber insurance underwriting requirements, much of which are now mandating multi-factor authentication or passwordless security solutions that BIO-key is well positioned to provide on a very competitive basis.
“We are also very bullish on the growth potential for passkey authentication this year and going forward. We entered this market with the recent launch of Passkey:YOU – BIO-key’s unique passwordless authentication solution that leverages our strength in biometric security to deliver secure passkeys without the use of phones or hardware tokens.
“We continue to pursue large enterprise opportunities through our direct sales channel, looking to build on recent successes in this area. We are also working to support our global channel partners in developing new customer opportunities to further build our end-user base. Our efforts have forged a growing base of high-margin annually recurring revenues (ARRs) and believe there is substantial potential to grow our ARR base moving forward. At the same time, we will continue to pursue cost reduction opportunities to accelerate our path to profitability and positive cash flow. We are also working to identify potential strategic opportunities to leverage our growing global base of customers to accelerate shareholder value creation. For these and other reasons, we believe BIO-key is well-positioned for the future.”
Financial Results
Q1’24 revenues of $2.2M were in line with similarly strong Q1’23 revenues. The current-year period was positively impacted by the expanded use of BIO-key’s biometric client identification system by a long-time financial services customer in South Africa. One large order from this customer in Q1’24 was the primary driver of a 23.6% increase in license fee revenues, offset by a decline in recurring and custom services and hardware revenue. Services revenue decreased due to the loss of one large service agreement and the absence of a large customer for Swivel Secure customizations and upgrades, which had occurred in Q1’23.
Gross profit grew over 100% to $1.9M in Q1’24 from $0.9M in Q1’23, reflecting the impact of $0.5M hardware reserve in Q1’23, as well as higher software license fee costs in Q1’23 related to royalty payments resulting from higher sales of our third-party Swivel Secure offerings. As a result, gross profit margin improved to 86% in Q1’24 vs. 40% in Q1’23, which includes a hardware reserve expense. Q1’24 gross margin also increased due to a revenue mix that included more high-margin license fee revenue.
Total operating expenses were reduced by approximately $0.2M or 9%, to $2.4M in Q1’24 from $2.6M in Q1’23, due to lower selling, general and administrative costs (SG&A) and lower research, development and engineering expenses (RD&E). SG&A decreased $148,759 (8%) to $1.8M in Q1’24, due to reductions in administration, sales personnel costs and marketing show expenses, including lower lease expense for our NJ headquarters versus Q1’23, partially offset by higher audit and reporting expenses. In Q3 of 2023, we were able to downsize our corporate headquarters, as many of our team now work remotely, which benefitted Q1’24 vs. Q1’23. RD&E also declined by $82,638 (12%) to $607,521, due to reductions in personnel, related benefits and outside services expenses.
Reflecting revenue strength and lower operating costs, BIO-key trimmed its net loss by 70% to $510,285, or $0.32 per share, in Q1’24 from $1.7M, or $3.51 per share, in Q1’23.
Balance Sheet
At March 31, 2024, BIO-key had current assets of approximately $2.3M, including $690,449 of cash and cash equivalents, $710,026 of net accounts receivable and due from factor, and $440,194 of inventory.
Conference Call Details
Date / Time: Tuesday, June 18th at 10 a.m. ET
Call Dial In #: 1-877-418-5460 U.S. or 1-412-717-9594 Int’l
Live Webcast / Replay: Webcast & Replay Link – Available for 3 months.
Audio Replay: 1-877-344-7529 U.S. or 1-412-317-0088 Int’l; code 1988012
About BIO-key International, Inc. (www.BIO-key.com)
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.
BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; our ability to integrate the operations and personnel of Swivel Secure into our business; fluctuations in foreign currency exchange rates; delays in the development of products, the commercial, reputational and regulatory risks to our business that may arise as a consequence the restatement of our financial statements, including any consequences of non-compliance with Securities and Exchange Commission (“SEC”) and Nasdaq periodic reporting requirements; our temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future; any disruption to our business that may occur on a longer-term basis should we be unable to remediate during fiscal year 2024 certain material weaknesses in our internal controls over financial reporting, and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
Engage with BIO-key
Facebook – Corporate: https://www.facebook.com/BIOkeyInternational/
LinkedIn – Corporate: https://www.linkedin.com/company/bio-key-international
Twitter – Corporate: @BIOkeyIntl
Twitter – Investors: @BIO_keyIR
StockTwits: BIO_keyIR
Investor Contacts
William Jones, David Collins
Catalyst IR
BKYI @Bacchus-9800
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
Three Months Ended
March 31,
2024 2023
Revenues
Services $ 213,122 $ 532,522
License fees 1,950,434 1,578,556
Hardware 17,647 72,689
Total revenues 2,181,203 2,183,767
Costs and other expenses
Cost of services 138,849 154,801
Cost of license fees 148,221 620,881
Cost of hardware 12,573 44,592
Cost of hardware - reserve - 500,000
Total costs and other expenses 299,643 1,320,274
Gross profit 1,881,560 863,493
Operating Expenses
Selling, general and administrative 1,782,973 1,931,732
Research, development and engineering 607,521 690,159
Total Operating Expenses 2,390,494 2,621,891
Operating loss (508,934 ) (1,758,398 )
Other income (expense)
Interest income 5 4
Loss on foreign currency transactions - (15,000 )
Change in fair value of convertible note - 141,991
Interest expense (1,356 ) (56,919 )
Total other income (expense), net (1,351 ) 70,076
Loss before provision for income tax (510,285 ) (1,688,322 )
Provision for (income tax) tax benefit - -
Net loss $ (510,285 ) $ (1,688,322 )
Comprehensive loss:
Net loss $ (510,285 ) $ (1,688,322 )
Other comprehensive income (loss) – Foreign currency translation adjustment (62,275 ) 72,146
Comprehensive loss $ (572,560 ) $ (1,616,176 )
Basic and Diluted Loss per Common Share $ (0.32 ) $ (3.51 )
Weighted Average Common Shares Outstanding:
Basic and diluted 1,615,323 480,833
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
March 31, December 31,
2024 2023
(Unaudited)
ASSETS
Cash and cash equivalents $ 690,449 $ 511,400
Accounts receivable, net 701,776 1,201,526
Due from factor 8,250 99,320
Inventory 440,194 445,740
Prepaid expenses and other 427,685 364,171
Total current assets 2,268,354 2,622,157
Equipment and leasehold improvements, net 198,238 220,177
Capitalized contract costs, net 349,145 229,806
Operating lease right-of-use assets 23,220 36,905
Intangible assets, net 1,329,985 1,407,990
Total non-current assets 1,900,588 1,894,878
TOTAL ASSETS $ 4,168,942 $ 4,517,035
LIABILITIES
Accounts payable $ 1,212,071 $ 1,316,014
Accrued liabilities 1,189,520 1,305,848
Government loan – BBVA Bank, current portion 135,835 138,730
Deferred revenue, current 755,405 414,968
Operating lease liabilities, current portion 23,797 37,829
Total current liabilities 3,316,628 3,213,389
Deferred revenue, long term 143,727 28,296
Deferred tax liability 22,998 22,998
Government loan – BBVA Bank – net of current portion 149,861 188,787
Total non-current liabilities 316,586 240,081
TOTAL LIABILITIES 3,633,214 3,453,470
Commitments and Contingencies
STOCKHOLDERS’ EQUITY
Common stock — authorized, 170,000,000 shares; issued and outstanding; 1,814,414 and 1,032,777 of $.0001 par value at March 31, 2024 and December 31, 2023, respectively 181 103
Additional paid-in capital 126,092,496 126,047,851
Accumulated other comprehensive loss (39,454 ) 22,821
Accumulated deficit (125,517,495 ) (125,007,210 )
TOTAL STOCKHOLDERS’ EQUITY 535,728 1,063,565
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 4,168,942 $ 4,517,035
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended
March 31,
2024 2023
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss $ (510,285 ) $ (1,688,322 )
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation 23,808 13,242
Amortization of intangible assets 78,005 81,237
Change in fair value of convertible note - (141,991 )
Amortization of capitalized contract costs 38,665 37,529
Reserve for inventory - 500,000
Operating leases right-of-use assets 13,686 66,132
Share and warrant-based compensation for employees and consultants 47,790 59,373
Stock based directors’ fees 9,003 12,002
Bad debts 100,000 -
Change in assets and liabilities:
Accounts receivable 399,749 (898,881 )
Due from factor 91,070 (33,000 )
Capitalized contract costs (158,005 ) (8,739 )
Inventory 5,545 6,554
Prepaid expenses and other (63,513 ) 2,219
Accounts payable (116,012 ) 88,040
Accrued liabilities (104,257 ) (135,417 )
Deferred revenue 455,868 178,755
Operating lease liabilities (14,033 ) (67,544 )
Net cash provided by (used in) operating activities 297,084 (1,928,811 )
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures (1,869 ) -
Net cash used in investing activities (1,869 ) -
CASH FLOW FROM FINANCING ACTIVITIES:
Deferred offering costs (13,470 ) -
Proceeds for exercise of warrants 1,400 -
Repayment of government loan (41,821 ) (34,289 )
Net cash used in financing activities (53,891 ) (34,289 )
Effect of exchange rate changes (62,275 ) 49,913
NET DECREASE IN CASH AND CASH EQUIVALENTS 179,049 (1,913,187 )
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 511,400 2,635,522
CASH AND CASH EQUIVALENTS, END OF PERIOD $ 690,449 $ 722,335
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.
News
Market Data
Register for real-time alerts, custom portfolio, and market movers
Ask ADVFN Intelligence (AI)
subslover
1 month ago
ecmoney
1 month ago
TheFinalCD
1 month ago
glenn1919
1 month ago
Monksdream
1 month ago
luckydude777
2 months ago
Invest-in-America
3 months ago
